The Cooper Companies, Inc. (NASDAQ:COO) Position Lessened by KBC Group NV

KBC Group NV decreased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 248,923 shares of the medical device company’s stock after selling 9,537 shares during the period. KBC Group NV owned 0.12% of Cooper Companies worth $22,884,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of COO. State Street Corp lifted its stake in shares of Cooper Companies by 1.2% in the 3rd quarter. State Street Corp now owns 8,590,689 shares of the medical device company’s stock valued at $947,897,000 after purchasing an additional 104,521 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Cooper Companies by 13.2% during the third quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock valued at $543,979,000 after buying an additional 573,908 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Cooper Companies by 1.0% in the third quarter. Geode Capital Management LLC now owns 4,796,556 shares of the medical device company’s stock worth $527,476,000 after buying an additional 48,559 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Cooper Companies by 23.0% during the 3rd quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock worth $435,856,000 after acquiring an additional 737,726 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Cooper Companies by 11.9% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,818,610 shares of the medical device company’s stock valued at $200,665,000 after acquiring an additional 194,118 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Analysts Set New Price Targets

COO has been the subject of a number of recent analyst reports. Citigroup decreased their target price on Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, December 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a report on Friday, December 6th. Wells Fargo & Company lifted their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Friday, December 6th. StockNews.com cut shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, Morgan Stanley lowered their price target on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Friday, December 6th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $117.00.

Cooper Companies Trading Down 1.0 %

Cooper Companies stock opened at $98.50 on Wednesday. The Cooper Companies, Inc. has a 12 month low of $84.76 and a 12 month high of $112.38. The stock has a market cap of $19.66 billion, a price-to-earnings ratio of 50.51, a price-to-earnings-growth ratio of 2.41 and a beta of 0.99. The business has a 50 day moving average price of $95.94 and a two-hundred day moving average price of $99.55. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.00 by $0.04. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same period last year, the business earned $0.87 earnings per share. Cooper Companies’s quarterly revenue was up 9.8% compared to the same quarter last year. As a group, equities analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.